Cellectar Biosciences Q1 EPS $(1.33) Beats $(1.89) Estimate. Cash And Equivalents $8.35M

Benzinga Newsdesk www.benzinga.com Negative 64.1%

Neg 64.1% Neu 0% Pos 0%

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.33) per share which beat the analyst consensus estimate of $(1.89) by 29.26 percent. This is a 69.07 percent increase over losses of $(4.30) per share from the same period last year.